Hyperphosphatemia Drugs MarketDrivers
Increasing launches and approvalof novel drugs in key regions are expected to fuel the global HyperphosphatemiaDrugs Market growth in near future. For instance, in 2016, Astellas PharmaInc. received marketing approval for its Kiklin Granules 86.2%, indicated forthe treatment of hyperphosphatemia in patients with chronic kidney disease inJapan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from EuropeanCommission for new drug Fexeric (R) (ferric citrate coordination complex),indicated for the treatment of hyperphosphatemia in adults with chronic kidneydisease.
In 2014, KeryxBiopharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA)approval for drug Ferric Citrate (formerly known as Zerenex), a new, oraliron-based treatment for dialysis patients with hyperphosphatemia. In 2014,Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia (ferric citrate)tablets. Auryxia is an absorbable iron-based phosphate binder indicated for thetreatment of hyperphosphatemia in chronic kidney disease
Strategic merger and acquisitionby key players in the market is also expected to create a lucrative environmentfor the hyperphosphatemia drugs market growth. For instance, in 2013, OPKOHealth, Inc. acquired Canada-based Cytochroma Inc., with this strategicacquisition OPKO Health, Inc. has expanded its portfolio with Cytochroma Inc.’sAlpharen, a non-absorbed phosphate binder to treat hyperphosphatemia indialysis patients.
Hyperphosphatemia is a conditioncaused due to high level of phosphate or phosphorous in the blood. Phosphate isa chemical found in body and contain mineral called phosphorous. Phosphorusmineral is very important for the development of teeth and bones and also convertfood into energy for body.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1976
Phosphate is mainly found in theteeth, bones, inside the cells, and in very smaller amounts in the blood.Kidney functions for the management of phosphate level in the body. However,various complications/diseases results into impairment of kidney, which leadsto chronically high level of phosphate in blood.
Hyperphosphatemia is very commonin people with chronic kidney disease more often in people with end-stagekidney disease. Some other possible causes of hyperphosphatemia includesdiabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and lowparathyroid hormone levels.
Furthermore, risk of developinghyperphosphatemia is very high in the people suffering from chronic kidneydisease. Hence, increasing prevalence of chronic kidney disease is expected toincrease the chances of hyperphosphatemia among population, which in turn isexpected to increase demand for hyperphosphatemia drugs and drive hyperphosphatemiadrugs market growth.
For instance, according to thedata published in National Chronic Kidney Disease Fact Sheet 2017, an estimated30 million people or 15% of U.S. adults are suffering from chronic kidneydisease. Chronic kidney diseases were estimated to be more common in Women (16%)as compared to men (13%).
Hyperphosphatemia Drugs MarketRegional Analysis
North America is expected to holda dominant position in global hyperphosphatemia drugs market and it is expectedto account for largest market size, due to presence of key players in regionand frequent research and development activities by them for development ofnovel drugs for treatment of hyperphosphatemia.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/hyperphosphatemia-drugs-market-1976
For instance, in 2017, U.S.-basedArdelyx, Inc. received positive results in Phase 3 clinical trial for new drugTenapanor. Tenapanor is a first-in-class, proprietary, oral, experimentalmedication indicated for the treatment of hyperphosphatemia in patients withend-stage renal disease.
Furthermore, Asia Pacifichyperphosphatemia drugs market is expected to witness significant growth innear future owing to increasing approval of novel hyperphosphatemia treatmentdrug in key regions such as China, and Japan. For instance, in 2014, JapanTobacco Inc. and its subsidiary Torii Pharmaceutical Co., Ltd. receivedmanufacturing and marketing approval of Riona Tablets 250 mg from JapaneseMinistry of Health, Labor and Welfare. Riona tablet is indicated for treatmentof hyperphosphatemia, it is a new phosphate binder containing ferric citratehydrate as the active pharmaceutical ingredient.
Hyperphosphatemia Drugs MarketKey Players
Key players operating in globalhyperphosphatemia drugs market include: Keryx Biopharmaceuticals, Inc.,Astellas Pharma Inc., Japan Tobacco Inc., Ardelyx, Inc., OPKO Health, Inc.,BioLink Life Sciences, Inc., F Hoffmann-La Roche AG, Lupin Limited, FreseniusMedical Care, and Vifor Pharma Group.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1976
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
